Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?
Research Directions Depression October 13, 2023 Ian B. Hickie, F. Markus Leweke, Allan H. Young 1 citation
Interest in evaluating the therapeutic value of psychedelic compounds for treatment-resistant depression has grown among research groups and the wider recreational drug-using community. This enthusiasm accompanies advocacy for decriminalization, legalization, and public licensing of these substances for medicinal use.